Lytix Biopharma AS (STU:6BG) Long-Term Debt : €0.00 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lytix Biopharma AS Long-Term Debt?

Lytix Biopharma AS's Long-Term Debt for the quarter that ended in Sep. 2024 was €0.00 Mil.

Lytix Biopharma AS Long-Term Debt Historical Data

The historical data trend for Lytix Biopharma AS's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lytix Biopharma AS Long-Term Debt Chart

Lytix Biopharma AS Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

Lytix Biopharma AS Quarterly Data
	Dec18	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Lytix Biopharma AS (STU:6BG) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Lytix Biopharma AS Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Lytix Biopharma AS's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Lytix Biopharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lytix Biopharma AS (STU:6BG) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

LYTIX:Norway

Address

Sandakerveien 138, Oslo, NOR, 0484

Website

https://www.lytixbiopharma.com

Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its products, LTX-401, and LTX-315 are in the pipeline.

Lytix Biopharma AS Headlines

No Headlines